ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-PO1199

Clinical Trials in Nephrology: An Updated Systematic Review of

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical


  • Mustafa, Reem, University of Kansas, Kansas City, Kansas, United States
  • Husainat, Nedaa, University of Kansas, Kansas City, Kansas, United States
  • Kalot, Mohamad A., University of Kansas, Kansas City, Kansas, United States
  • El alayli, Abdallah, Lebanese American University, Beirut, Lebanon
  • Shaaban, Adnan, University of Minnesota, St. Paul, Minnesota, United States
  • Numan, Laith, University of Missouri, Kansas City, Missouri, United States
  • Alkhatib, Mohammed N., University of Kansas, Kansas City, Kansas, United States
  • Sekercioglu, Nigar, McMaster University, Hamilton, Ontario, Canada
  • Nizamuddin, Raabia, University of Kansas, Kansas City, Kansas, United States
  • Ishida, Julie H., Gilead Sciences, San Francisco, California, United States
  • West, Melissa, American Society of Nephrology, Washington, District of Columbia, United States
  • Tibbs, Sheri, Duke University, Durham, North Carolina, United States
  • Patel, Uptal D., Gilead Sciences, Inc., Foster City, California, United States
  • Inrig, Jula K., IQVIA; UC Irvine; Duke University, Yorba Linda, California, United States

Previously published reviews have highlighted low rates and poor quality of clinical trials in nephrology compared to other specialties. In this review, we assessed temporal trends in the quantity and quality of nephrology trials.


We conducted a systematic review among nephrology trials registered on from inception to November 2018. Two independent reviewers assessed every trial and extracted data.


A database of 288,515 registered interventional trials was restricted to studies that included one of 154 nephrology terms. We screened 5412 studies and included 4943 in the analysis. Figure 1 summarizes the number of registered nephrology trials over time. Trials were grouped into 3 Eras [Table 1]. Compared to Era 1, Era 3 had more randomized, blinded, and large trials. Fewer studies were NIH and industry-funded. Drug trials decreased while device and behavioral interventions increased. While there was a decrease in transplant trials, there was an increase in living donor recipient and in glomerular disease trials.


There has been an increase in the number of nephrology trials conducted over time with some improvement in quality and an increase in trials for devices, behavioral interventions, and rare kidney diseases.

Table 1Era 1: 09/30/1982 - 08/31/2010Era 2: 09/01/2010 - 08/31/2014Era 3: 09/01/2014 - 11/31/2018
> 1000 Patient Enrollment1.5%2%4.1%
NIH Funded8%4.5%6.6%
Industry Funded45.3%42.8%32.2%
Drug Intervention73.5%64.5%57.2%
Device Intervention6%8.9%10.7%
Behavioral Intervention2.7%4%6.2%
Glomerular Disease5.8%6%7.5%
Renal Transplant (living donor recipient out of all renal transplant trials12.7%